West Pharmaceutical Services Inc (WST) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Total Cash From Operating Activities Chart for West Pharmaceutical Services Inc
West Pharmaceutical Services Inc (WST) operating cash flow for FY2025 was USD 754.8M, a 15.5% change from FY2024. West Pharmaceutical Services Inc's operating cash flow grew from USD 42.9M in 1989 to USD 754.8M in 2025 (1659.4% over 36 years). Operating cash flow compound annual growth rate: 5-year CAGR of 9.8%, 10-year CAGR of 13.5%, 20-year CAGR of 11.5%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $24.53B
- Implied Share Price
- $348.60
- Enterprise Value
- $24.42B
- Revenue (TTM)
- $3.33B
- EBITDA
- $912.20M
- Profit Margin
- 16.98%
- Trailing P/E
- 45.04
- Forward P/E
- 39.53
- Price/Book (MRQ)
- 8.21
- Price/Sales (TTM)
- 7.37
- EV/EBITDA
- 27.77
- EV/Revenue
- 7.34
- Dividend Yield
- 0.25%
- Book Value
- $42.47
- Free Cash Flow (FY2025)
- $468.90M
- Free Cash Flow Yield
- 1.91%
Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.